Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).
Journal of Clinical Oncology (2018)
  • William G. Wierda, University of Texas MD Anderson Cancer Center
  • Tanya Siddiqi, City of Hope National Medical Center
  • Ian Flinn, Sarah Cannon Research Institute
  • Xavier C. Badoux, St George's Hospital
  • Thomas J. Kipps, University of California, San Diego
  • John N. Allan, NewYork–Presbyterian Hospital
  • Alessandra Tedeschi, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy;
  • John M. Pagel, Swedish Cancer Institute, Seattle, WA;
  • Bryone J. Kuss, Flinders Medical Centre
  • Eva González Barca, Institut Català d'Oncología L’Hospitalet, Barcelona, Spain;
  • Paolo Ghia, Vita-Salute San Raffaele University
  • Karl Eckert, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA;
  • Cathy Zhou, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA;
  • Joi Ninomoto, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA;
  • James P. Dean, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA;
  • Danelle Frances James, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA;
  • Constantine Tam, Peter MacCallum Cancer Centre
Link
Disciplines
Publication Date
May 20, 2018
DOI
10.1200/jco.2018.36.15_suppl.7502
Citation Information
William G. Wierda, Tanya Siddiqi, Ian Flinn, Xavier C. Badoux, et al.. "Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL)." Journal of Clinical Oncology Vol. 36 (2018) p. 7502 - 7502
Available at: http://works.bepress.com/john-pagel/301/